文献速递临床试验与 GCP流行病学与生物统计

基于贝叶斯波段的自适应N-of-1临床试验设计

A Bayesian-bandit adaptive design for N-of-1 clinical trials.
PubMed 文献 · Stat Med · 2021-01-18

针对单受试者随机双盲多周期交叉的N-of-1试验,提出基于多臂波段框架的贝叶斯自适应设计,用汤普森采样按后验概率分配治疗,并通过贝叶斯分层结构联合建模个体与群体效应。模拟研究表明,该设计从以患者为中心的角度可能使受试者获益,尤其对偏离总体群体效应的个体。

要点

  • 该设计可同时估计个体和群体治疗效应,适用于RCT不可行的场景。
  • 汤普森采样依据贝叶斯后验概率随机分配治疗,分层模型通过收缩借力群体估计。
  • 模拟研究显示偏离群体效应的个体可能从该自适应设计中获益。

核心结论

  • 提出的贝叶斯自适应N-of-1设计通过分层建模与汤普森采样,可能使受试者从患者中心角度获益,尤其对偏离总体群体效应的个体。

研究设计与样本

  • 研究为方法学模拟研究,提出基于多臂波段框架的贝叶斯自适应设计,采用马尔可夫链蒙特卡洛估计,并用贝叶斯分层结构联合建模个体与群体治疗效应。
  • 模拟研究受一项近期完成的N-of-1临床试验启发,用于展示设计的工作特征与性能。

主要发现

  • 模拟研究表明,从以患者为中心的角度,受试者可能从该自适应设计中获益,尤其对偏离总体群体效应的个体。

临床怎么用

  • 在RCT不可行时,可考虑采用聚合N-of-1设计及所提贝叶斯自适应方法,以个体化分配治疗并估计群体效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

N-of-1 trials, which are randomized, double-blinded, controlled, multiperiod, crossover trials on a single subject, have been applied to determine the heterogeneity of the individual's treatment effect in precision medicine settings. An aggregated N-of-1 design, which can estimate the population effect from these individual trials, is a pragmatic alternative when a randomized controlled trial (RCT) is infeasible. We propose a Bayesian adaptive design for both the individual and aggregated N-of-1 trials using a multiarmed bandit framework that is estimated via efficient Markov chain Monte Carlo. A Bayesian hierarchical structure is used to jointly model the individual and population treatment effects. Our proposed adaptive trial design is based on Thompson sampling, which randomly allocates individuals to treatments based on the Bayesian posterior probability of each treatment being optimal. While we use a subject-specific treatment effect and Bayesian posterior probability estimates to determine an individual's treatment allocation, our hierarchical model facilitates these individual estimates to borrow strength from the population estimates via shrinkage to the population mean. We present the design's operating characteristics and performance via a simulation study motivated by a recently completed N-of-1 clinical trial. We demonstrate that from a patient-centered perspective, subjects are likely to benefit from our adaptive design, in particular, for those individuals that deviate from the overall population effect.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Shrestha S, Jain S. A Bayesian-bandit adaptive design for N-of-1 clinical trials. Stat Med. 2021. PMID: 33462851. doi:10.1002/sim.8873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。